J&J Units Pay 65 Million to Settle Tracleer Antitrust Case
J&J units will pay $65 million to settle claims they delayed generic versions of Tracleer. The deal compensates health plans for alleged overcharges since 2015.
Xurve View
Insights:
Xurve View
Two subsidiaries of Johnson & Johnson have reached a $65 million preliminary settlement to resolve a class-action antitrust lawsuit in the United States. The litigation, filed by health plans and other third-party payers, alleged that the pharmaceutical giant overcharged for the pulmonary hypertension medication Tracleer by delaying the entry of generic competitors.
